Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clozapine-induced hypersalivation.

L Davydov1, S R Botts

  • 1College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, NY, USA.

The Annals of Pharmacotherapy
|June 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tenecteplase: a review.

Clinical therapeutics·2001
Same author

Olanzapine-induced diabetes mellitus.

The Annals of pharmacotherapy·2001
Same author

The association of infection and coronary artery disease: an update.

Expert opinion on investigational drugs·2000
Same author

Outcomes of weight-based heparin dosing based on literature guidelines and institution individualization.

Pharmacotherapy·2000
Same author

Gabapentin and lamotrigine in bipolar disorder.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same author

Atypical antipsychotics in the managed care era.

The American journal of managed care·1997
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Clozapine-induced hypersalivation affects up to 54% of patients. Management strategies include dose reduction, chewing gum, or medications like anticholinergics.

Area of Science:

  • Pharmacology
  • Neuroscience

Background:

  • Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia.
  • Hypersalivation (sialorrhea) is a common and distressing side effect of clozapine therapy.

Purpose of the Study:

  • To review the pathophysiology of clozapine-induced hypersalivation.
  • To explore potential treatment options for this adverse effect.

Main Methods:

  • A literature search was conducted using MEDLINE from 1966 to May 1999.
  • Keywords included clozapine, hypersalivation, sialorrhea, and treatment.

Main Results:

  • Hypersalivation affects a significant portion of patients, occurring in up to 54%.
  • Studies and case reports on managing clozapine-induced hypersalivation were evaluated.

Related Experiment Videos

Conclusions:

  • The exact mechanism of clozapine-induced hypersalivation remains unclear, with potential roles for muscarinic M4 receptor activation or alpha2-adrenoceptor blockade.
  • Possible etiological factors include altered swallowing reflexes.
  • Treatment options encompass behavioral interventions (gum chewing), dose adjustment, and pharmacotherapy (anticholinergics, alpha2-adrenoceptor agonists).